Immunotherapy has been a remarkable clinical advancement in the treatment of cancer. T
cells are pivotal to the efficacy of current cancer immunotherapies, including immune …

Immunotherapy has revolutionized cancer treatment, but efficacy remains limited in most
clinical settings. Cancer is a systemic disease that induces many functional and …

CD8+ T cell responses are critical for anti-tumor immunity. While extensively profiled in the
tumor microenvironment, recent studies in mice identified responses in lymph nodes (LNs) …

Summary Blocking PD-1/PD-L1 signaling transforms cancer therapy and is assumed to
unleash exhausted tumor-reactive CD8+ T cells in the tumor microenvironment (TME) …

Strategies to therapeutically target the tumor microenvironment (TME) have emerged as a
promising approach for cancer treatment in recent years due to the critical roles of the TME …

Neoadjuvant immune checkpoint blockade has shown promising clinical activity. Here, we
characterized early kinetics in tumor-infiltrating and circulating immune cells in oral cancer …

The tumor development and metastasis are closely related to the structure and function of
the tumor microenvironment (TME). Recently, TME modulation strategies have attracted …

Summary PD-1/PD-L1-checkpoint blockade therapy is generally thought to relieve tumor cell-
mediated suppression in the tumor microenvironment but PD-L1 is also expressed on non …

Immune checkpoint blockade therapies have shown clinical promise in a variety of cancers,
but how tumor-infiltrating T cells are activated remains unclear. In this study, we explore the …

In tumors, a subset of CD8+ T cells expressing the transcription factor TCF-1 drives the
response to immune checkpoint blockade. We examined the mechanisms that maintain …